NEW YORK (360Dx) — SQI Diagnostics announced today that it has partnered with Toronto-based University Health Network to create a rapid, multiplex test and companion point-of-care device for identifying lung transplant candidates.
Under the terms of the deal, Toronto-based SQI will work with scientists at UHN's Toronto Lung Transplant Program to develop the products. Additional terms were not disclosed.
The technology to be developed will leverage predictive biomarkers developed at UHN to evaluate the suitability of a lung for transplant, SQI said. It added that the partnership would also expand the use of the developed device to organs other than lung.
"This agreement represents a reputational landmark for SQI … [and] also represents a major long-term commercialization opportunity," SQI CEO Andrew Morris said in a statement. "SQI's multi-array testing is proving to be applicable in areas well beyond drug development and disease identification."